Med Life 将来の成長

Future 基準チェック /56

Med Life利益と収益がそれぞれ年間92.9%と11.5%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に24.4% 93.7%なると予測されています。

主要情報

92.9%

収益成長率

93.7%

EPS成長率

Healthcare 収益成長	24.3%
収益成長率	11.5%
将来の株主資本利益率	24.4%
アナリストカバレッジ	Low
最終更新日	27 Nov 2024

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

BVB:M - アナリストの将来予測と過去の財務データ ( )RON Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	3,301	187	442	N/A	1
12/31/2025	2,947	89	314	N/A	1
12/31/2024	2,626	24	N/A	N/A	1
9/30/2024	2,566	22	10	272	N/A
6/30/2024	2,461	18	26	274	N/A
3/31/2024	2,337	11	-15	223	N/A
12/31/2023	2,222	4	-36	184	N/A
9/30/2023	2,116	-11	40	268	N/A
6/30/2023	2,020	-3	-10	179	N/A
3/31/2023	1,921	12	23	212	N/A
12/31/2022	1,810	32	15	185	N/A
9/30/2022	1,725	64	10	112	N/A
6/30/2022	1,623	80	83	202	N/A
3/31/2022	1,520	98	122	209	N/A
1/1/2022	1,438	103	130	227	N/A
9/30/2021	1,359	107	103	185	N/A
6/30/2021	1,295	112	67	172	N/A
3/31/2021	1,160	83	47	148	N/A
1/1/2021	1,087	57	40	129	N/A
9/30/2020	1,033	36	49	145	N/A
6/30/2020	974	16	77	134	N/A
3/31/2020	1,007	18	63	113	N/A
12/31/2019	975	14	54	107	N/A
9/30/2019	939	20	32	76	N/A
6/30/2019	902	16	28	71	N/A
3/31/2019	861	11	N/A	N/A	N/A
1/1/2019	804	13	-1	52	N/A
9/30/2018	745	8	0	47	N/A
6/30/2018	699	5	N/A	41	N/A
3/31/2018	657	5	N/A	N/A	N/A
1/1/2018	628	4	N/A	36	N/A
9/30/2017	610	3	N/A	42	N/A
6/30/2017	577	-2	N/A	39	N/A
3/31/2017	539	-6	N/A	N/A	N/A
1/1/2017	508	-5	N/A	43	N/A
9/30/2016	469	-1	N/A	39	N/A
12/31/2015	396	9	N/A	42	N/A
12/31/2014	337	7	N/A	36	N/A
12/31/2013	306	-4	N/A	23	N/A

アナリストによる今後の成長予測

収入対貯蓄率: Mの予測収益成長率 (年間92.9% ) は貯蓄率 ( 6.3% ) を上回っています。

収益対市場: Mの収益 ( 92.9% ) はRO市場 ( -0.3% ) よりも速いペースで成長すると予測されています。

高成長収益: Mの収益は今後 3 年間で大幅に増加すると予想されています。

収益対市場: Mの収益 ( 11.5% ) RO市場 ( 1.5% ) よりも速いペースで成長すると予測されています。

高い収益成長: Mの収益 ( 11.5% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: Mの自己資本利益率は、3年後には高くなると予測されています ( 24.4 %)

Med Life 将来の成長

Future 基準チェック /56

主要情報

今後の成長に関する最新情報

Consensus EPS estimates fall by 20%

Consensus EPS estimates increase by 25%

Price target increased by 11% to RON5.71

Price target decreased by 7.3% to RON20.21

Price target increased by 31% to RON20.45

Price target decreased to RON19.50

Recent updates

Consensus EPS estimates fall by 20%

Third quarter 2024 earnings released

Med Life S.A. (BVB:M) acquired 60% stake in Routine Med S.r.l.

Med Life S.A. (BVB:M) acquired 80% stake in Euromedica Hospital Sa.

Consensus EPS estimates increase by 25%

Price target increased by 11% to RON5.71

Second quarter 2024 earnings released

Is Med Life S.A. (BVB:M) Trading At A 41% Discount?

Now 28% undervalued

Now 22% undervalued

The Market Lifts Med Life S.A. (BVB:M) Shares 25% But It Can Do More

Full year 2023 earnings released: EPS: RON0.007 (vs RON0.061 in FY 2022)

Is Med Life (BVB:M) A Risky Investment?

Full year 2023 earnings released: EPS: RON0.007 (vs RON0.061 in FY 2022)

Full year 2023 earnings released

Med Life S.A. to Report First Half, 2024 Results on Aug 30, 2024

Third quarter 2023 earnings released

Second quarter 2023 earnings released

Price target decreased by 7.3% to RON20.21

Returns On Capital Signal Tricky Times Ahead For Med Life (BVB:M)

First quarter 2023 earnings released

Full year 2022 earnings released: EPS: RON0.30 (vs RON0.77 in FY 2021)

Price target increased by 31% to RON20.45

Med Life S.A., Annual General Meeting, Apr 27, 2023

Med Life S.A. (BVB:M) acquired 99.76% stake in Muntenia Medical Competences SA.

Is Med Life (BVB:M) A Risky Investment?

Med Life (BVB:M) Hasn't Managed To Accelerate Its Returns

Third quarter 2022 earnings released

Less than half of directors are independent

Third quarter 2022 earnings released

Med Life S.A. (BVB:M) completed the acquisition of 80% stake in Medici's Group.

We Think Med Life (BVB:M) Is Taking Some Risk With Its Debt

Price target decreased to RON19.50

Med Life S.A. (BVB:M) acquired majority stake in SanoPass SRL.

Med Life S.A. (BVB:M) acquired majority stake in SanoPass SRL.

Second quarter 2022 earnings released

Med Life S.A. (BVB:M) acquired 60% stake in Opticristal - ophthalmological clinic.

Med Life S.A. (BVB:M) agreed to acquire SWEAT CONCEPT ONE.

Med Life S.A. (BVB : M) acquired Medicris Oradea Group.

Med Life S.A. (BVB:M) entered into an agreement to acquire 80% stake in Medici's Group.

Price target increased to RON26.13

Returns Are Gaining Momentum At Med Life (BVB:M)

Less than half of directors are independent

Med Life S.A. (BVB:M) acquired 60% interest in Pro Life Clinics.

Investor sentiment deteriorated over the past week

Is There An Opportunity With Med Life S.A.'s (BVB:M) 49% Undervaluation?

Med Life S.A. (BVB:M) completed the acquisition of 50% stake in Neolife Medical Center Romania.

Med Life (BVB:M) Shareholders Will Want The ROCE Trajectory To Continue

Third quarter 2021 earnings released

Price target increased to RON17.40

Price target increased to RON14.65

Does Med Life (BVB:M) Have A Healthy Balance Sheet?

Med Life's (BVB:M) Returns On Capital Are Heading Higher

Med Life S.A. (BVB:M) acquired remaining 10% stakes in Clinica Medicala Panduri.

Med Life S.A. (BVB:M) acquired the remaining 10% stake in Centrul Medical Panduri S.A.

Here's Why We Think Med Life (BVB:M) Is Well Worth Watching

Is Now An Opportune Moment To Examine Med Life S.A. (BVB:M)?

Is There An Opportunity With Med Life S.A.'s (BVB:M) 24% Undervaluation?

Med Life S.A. (BVB:M) acquired 60% stake in Medica Sibiu.

Update: Med Life (BVB:M) Stock Gained 98% In The Last Year

Should We Be Excited About The Trends Of Returns At Med Life (BVB:M)?

Revenue and earnings beat expectations

Full year 2020 earnings released

Should You Be Impressed By Med Life S.A.'s (BVB:M) ROE?

Med Life (BVB:M) Seems To Use Debt Quite Sensibly

Price target raised to RON8.47

Is It Too Late To Consider Buying Med Life S.A. (BVB:M)?

Do Med Life's (BVB:M) Earnings Warrant Your Attention?

New 90-day high: RON11.20